Pearl Huang

Company: Dunad Therapeutics

Job title: CEO

Seminars:

Panel Discussion: How do we Differentiate Degraders from Inhibitors as a Therapeutic Modality? 10:00 am

How do we break away from the inhibitor-based ligands like BRAF? Do we need to? How are we finding new, exciting targets? How do we address the problems with VHL pharmacology such as its larger size?Read more

day: Conference Day Two